Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction

27 August 2022 (09:36 - 09:48)
Organised by:
Congress Presentation Part of: HFpEF and HFmrEF: what’s new in treatment? Heart Failure with Mid-Range Ejection Fraction (HFmrEF) ESC Professional Premium Access ESC Congress 2022

ESC 365 is supported by

ESC 365 is supported by